Additionally, NUTM1 subtype showed subtype-specific expression of ZNF311, which is potentially a novel biomarker for assessing prognosis and immune infiltration in glioblastoma[56] (Figure 6S). This evidence concerns the gene NUTM1 and glioblastoma.